Abstract:Our objective was to develop an array of alpha(7)-selective nicotinic cholinergic receptor (nAChR)-based imaging agents for PET and SPECT. Methods: (2'R)-N-C-11-Methyl-N-(phenylmethyl)-spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridin]-5'-amine 1 was synthesized by reaction of the corresponding desmethyl precursor with C-11-CO2 and reduction. N-(R)-1-Aza-bicyclo[2.2.2]oct-3-yl-4-C-11-methylsulfanyl-benzamide 2 was synthesized by reduction of the corresponding disulfide precursor and reaction with C-11-iodomethane. N-(R)-1-Aza-bicyclo[2.2.2]oct-3-yl-4-'251-iodo-benzamide 3 was synthesized by halogen exchange of the corresponding bromide. (2'R)-5'-(2-I-125-iodo-3-furanyl)spiro[1-azabicyclo[2.2.2] octane]-3,2'(3'H)-furo[2,3-b]pyridine 4 was synthesized by the chloramine-T method. Kinetic biodistribution studies were done in male CD-1 mice by tail vein injection of 3.7 MBq (100 muCi) of the C-11-labeled radiotracer or 0.67 MBq (2 muCi) of the I-125-labeled radiotracer followed by brain dissection and tissue counting. Receptor blockade was determined by pretreatment of the mice with an excess of either unlabeled precursor or nicotine. Results: We synthesized 4 radiolabeled, moderate- to high-affinity, mu(7)-nAChR-based ligands. The compounds were a series of quinuclidine derivatives with an inhibition constant (K-i) < 6 nmol/L (33 pmol/L for 4) for alpha(7)-nAChR and selectivities of alpha(7)/alpha(4)beta(2) subtypes of greater than or equal to 14,000. All of the compounds were produced in adequate radiochemical yield and specific radioactivity (>74 GBq/mumol [2,000 Ci/mmol]). No site selectivity or receptor blockade was shown for 1 and 2 (0.91 +/- 0.05 and 0.14 +/- 0.03 %ID/g [percentage injected dose per gram] in the hippocampus [target tissue], respectively). Compound 3 showed low hippocampal uptake (0.25 +/- 0.05 %ID/g) but prolonged retention within that structure. Pretreatment with nicotine decreased its uptake by up to 50% in the hippocampus. Similar reductions were also observed within the cerebellum (nontarget tissue). Compound 4 showed hippocampal uptake of 2.41 +/- 0.03 %ID/g and target-to-nontarget uptake ratios of up to 2. Pretreatment of animals with unlabeled 4 resulted in a decrease of hippocampal uptake to 60% of its preblockade value without a corresponding decrease in cerebellar uptake. Conclusion: With further structural optimization, selective imaging of a7-nAChR may be possible.

Tritium labelling of several potent imidazoline receptor ligands

Radiosynthesis of Tritium-Labeled Novel Nitromethylene Neonicotinoids Compounds with NaB3H4

Tritium and deuterium labelling of a kainate receptor antagonist and evaluation as a radioligand

Dofetilide: tritium labelling by several methods

Radiolabelled Quinoline Derivaties for the PET Imaging of Peripheral Benzodiazepine Receptor

The Development and Application of Tritium-Labeled Compounds in Biomedical Research

Dually Labeled Neurotensin NTS1R Ligands for Probing Radiochemical and Fluorescence-Based Binding Assays

Microfluidics for synthesis of peptide-based PET tracers.

Two F-18 Radiochemistry Methods to Synthesize a Promising Transient Receptor Potential Canonical 5 (trpc5) Radioligand

Histamine H2 receptor radioligands: triumphs and challenges

Palladium(II)-Mediated C-H Tritiation of Complex Pharmaceuticals

Synthesis and biological characterization of novel 2-quinolinecarboxamide ligands of the peripheral benzodiazepine receptors bearing technetium-99m or rhenium

Synthesis and 125I labeling of a precursor for imaging nicotinic acetylcholine receptors

Radiolabelling small and biomolecules for tracking and monitoring

Probing the Conformation States of Neurotensin Receptor 1 Variants by NMR Site-Directed Methyl Labeling

Radiolabeling, docking studies, in silico ADME and biological evaluation of serotonin with 125I for 5-HTRs imaging

Preparation and preliminary evaluation of a tritium-labeled allosteric P2X4 receptor antagonist

Synthesis and biodistribution of radiolabeled alpha 7 nicotinic acetylcholine receptor ligands.

Nitrogen-containing cyclic compounds as iminium ion sources for selected reaction monitoring detection of derivatized analytes

A new 18F-RBF3 radioprosthetic for one step aqueous labeling of peptides and other ligands: meeting the challenge of radiosynthetic ease and preclinical impact i.e. high specific activity and high T:NT ratios

Selective Deuteration and Tritiation of Pharmaceutically Relevant Sulfoximines